A 75-year-old woman with anaplastic lymphoma kinase (ALK)-rearranged Stage IV lung
adenocarcinoma was administered the selective anaplastic lymphoma kinase inhibitor …

Interstitial lung disease (ILD) is a well-known adverse effect of mammalian target of
rapamycin (mTOR) inhibitors. However, it remains unknown how lung toxicities are induced …

We evaluated the association of signal transducer and activator of transcription 3 (STAT3)
polymorphisms with the incidence of mammalian target of rapamycin (mTOR) inhibitor …

Neuroendocrine tumors (NETs) consist of a diverse family of tumors which are derived from
the neuroendocrine system. Most NETs are well or moderately differentiated tumors with a …

What's known on the subject? and What does the study add? The side‐effect of targeted
agents is known. The clinician should be aware of the side‐effects of targeted agents and …

Introduction Noninfective pneumonitis is a class-related effect within mammalian target of
rapamycin (mTOR) inhibitors, including everolimus, and can occasionally be severe. Case …

Background The global BOLERO-2 trial established the efficacy and safety of combination
everolimus (EVE) and exemestane (EXE) in the treatment of estrogen receptor positive …

In the past decade, metastatic renal cell carcinoma (mRCC) treatment underwent significant
advancement that resulted in an unprecedented improvement in the prognosis of this …

The current standard of care for treating metastatic renal cell carcinoma is sequential
therapy with vascular endothelial growth factor-targeted agents (ie, axitinib, bevacizumab …

Abstract Background Exemestane (EXE), exemestane+ everolimus (EXE+ EVE), toremifene
(TOR), and fulvestrant (FUL) are second-line endocrine therapies for postmenopausal …